Drug – bio-affecting and body treating compositions – Identification or warning feature – Taste or smell or chemical irritation to the eye – nose – or...
Patent
1984-06-04
1985-10-15
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Identification or warning feature
Taste or smell or chemical irritation to the eye, nose, or...
514263, A61K 3152, A61K 920
Patent
active
045473587
ABSTRACT:
Non-disintegrating theophylline tablets having a pair of opposing substantially planar surfaces and a very thin cross-section have a high bioavailability on ingestion and a relatively steady release rate permitting a 12 hr. dosing interval for maintenance of non-toxic therapeutic blood theophylline concentrations. Excipients or tableting aids are not required, but trace amounts of a tableting lubricant are preferably included to facilitate continuous large scale production.
REFERENCES:
patent: 2980589 (1961-04-01), de Grunigen
patent: 3062720 (1962-11-01), Costello
patent: 3065143 (1962-11-01), Christenson et al.
patent: 3079303 (1963-02-01), Raff et al.
patent: 3080294 (1963-03-01), Shepard
patent: 3108046 (1963-10-01), Harbit
patent: 3133863 (1964-05-01), Tansey et al.
patent: 3147187 (1964-09-01), Playfair
patent: 3148124 (1964-09-01), Gaunt
patent: 3279995 (1966-10-01), Reid
patent: 3279998 (1966-10-01), Raff et al.
patent: 3344029 (1967-09-01), Berger
patent: 3402240 (1968-09-01), Cain et al.
patent: 3424842 (1969-01-01), Nurnberg
patent: 3456049 (1969-07-01), Hotko et al.
patent: 3507952 (1970-04-01), Rodnick et al.
patent: 3622677 (1971-11-01), Short et al.
patent: 3632778 (1972-01-01), Sheth et al.
patent: 3639169 (1972-02-01), Broeg et al.
patent: 3641236 (1972-02-01), Coppen et al.
patent: 3773920 (1973-11-01), Nakamoto et al.
patent: 3782993 (1974-01-01), Rothgang et al.
patent: 3852421 (1974-12-01), Koyanagi et al.
patent: 3870790 (1975-03-01), Lowey et al.
patent: 3908003 (1975-09-01), Hirsh
patent: 3950508 (1976-04-01), Mony et al.
patent: 4017598 (1977-04-01), Ohno et al.
patent: 4167558 (1979-09-01), Sheth et al.
patent: 4209513 (1980-06-01), Torode et al.
patent: 4215104 (1980-07-01), Ullman et al.
patent: 4226849 (1980-10-01), Schor
patent: 4258027 (1981-03-01), Ullman et al.
patent: 4259314 (1981-03-01), Lowey
patent: 4264573 (1981-04-01), Powell et al.
patent: 4465660 (1984-08-01), David et al.
Lachman et al., The Theory and Practice of Industrial Pharmacy, 2nd Ed., (1976) Lea & Febiger, Philadelphia, PA., pp. 321-358 (Tablets), 439-465 (Sustained Action Dosage Forms).
Chem. Abs. 95:175586j. Benedikt, Asthma-Ther. Theophillin Optim. Blutspiegel-Bestimm, Arbeitsgespraech, pp. 23-36 (1980).
Chem. Abs. 95:175666k. Sybrecht, Astham-Ther. Theophyllin Optim. Blutspiegel-Bestimm., Arbeitsgespraech, pp. 108-121 (1980).
Chem. Abs. 94:20311w. Upton, et al., J. Pharmacokinet. Biopharm., 8(2), 131-149 (1980).
Chem. Abs. 94:20319e. Upton, et al., J. Pharmacokinet. Biopharm., 8(3), 229-242 (1980).
Chem. Abs. 94:90146v. Barrett, Curr. Ther. Res., 28(5, Sect. 1) 669-681 (1980).
Chem. Abs. 93:12993j. Svedmyr, et al., Curr. Med. Res. Opin., 6(Suppl. 6), 40-44 (1979).
Chem. Abs. 93:12994k. Jonkman, et al., Curr. Med. Res. Opin., 6 (Suppl. 6) 71-76 (1979).
Chem. Abs. 93:13041j. Trembath, et al., Br. J. Clin. Pharmacol. 9(4), 365-369 (1980).
Chem. Abs. 93:31668y. Lipman, Mod. Med. Asia, 16(2), 59-60 (1980).
Chem. Abs. 93:31686c. French, et al., Curr. Med. Res. Opin. 6 (Suppl. 6) 3-13 (1979).
Chem. Abs. 93:245364v. Meyer, et al., Chest, 78(2), 300-303 (1980).
Chem. Abs. 92:11154d. Levitt, et al., Curr. Ther. Res., 26(3) 311-316 (1978).
Chem. Abs. 92:11163f. Clements, Arch. Pharm. Chemi., Sci. Ed., 7(4), 132-134 (1979).
Chem. Abs. 92:153027p. Sansom, et al., Eur. J. Clin. Pharmacol., 16(6), 417-421 (1979).
Chem. Abs. 92:203502n. Nielsen-Kudsk, et al., Acta. Pharmacol. Toxicol., 46(3), 205-212 (1980).
Chem. Abs. 91:44449m. Plavsic, et al., Lijec, Vjesn., 100(10), 610-612 (1978).
Chem. Abs. 91:78812q. Dasta, et al., Am. J. Hosp. Pharm., 36(5), 613-617 (1979).
Chem. Abs. 91:128945h. Apold, et al., Lancet, 1(8117), 667-668 (1979).
Chem. Abs. 90:12216w. Weinberger, et al., N. Engl. J. Med., 299(16), 852-857 (1978).
Chem. Abs. 88:110416q. Gilenberg, Isr. Pharm. J., 20(5), 254-242 (1977).
Chem. Abs. 88:177130k. Spangler, et al., Ann. Allergy, 40(1), 6-11 (1978).
Chem. Abs., 87:111184d. Hendeles, et al., Am. J. Hosp. Pharm., 34(5), 525-527 (1977).
Chem. Abs. 87:157084z. Fixley, et al., Am. Rev. Respir. Dis., 115(6, Pt. 1), 955-962 (1977).
Chem. Abs. 87:157116m. Kristofferson, et al., Acta. Pharm. Fenn., 86(2), 49-56 (1977).
Chem. Abs. 86:195084m. Kern, et al., Drug Intell. Clin. Pharm., 11(3), 144-153 (1977).
Chem. Abs. 85:51681k. Sims, et al., Br. J. Clin. Pharmacol., 3(1), 194-196 (1976).
Chem. Abs. 84:111563q. Welling, et al., J. Clin. Pharmacol. 16(1) 43-50 (1976).
Chem. Abs. 82:103076b. Mitenko, et al., Clin. Pharmacol., Ther., 16(4), 720-726 (1974).
Chem. Abs. 82:103072x. Graham, et al., Aust. J. Pharm. Sci., 3(2), 66-68 (1974).
Brooke Dana
David Stephen T.
Gallian Claude E.
Mead Johnson & Company
Rose Shep K.
Ryan Richard P.
Uloth Robert H.
LandOfFree
Sustained release tablet containing at least 95 percent theophyl does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release tablet containing at least 95 percent theophyl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release tablet containing at least 95 percent theophyl will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2431584